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The global burden of non-communicable diseases (NCDs) is of grave 
concern and has recently been highlighted by the World Health 
Organization (WHO) and a plethora of publications in prominent 
journals.[1-3] Chronic kidney disease (CKD) has often been indicated 
as a major contributing factor to this burden, especially in low- and 
middle-income countries.[4] Initial figures stated that CKD was present 
in 10% of the world’s population. Recently, this figure has risen to 
14% in the USA, and by 2030, 27% of North Americans >30 years of 
age are predicted to have CKD.[4] An added burden to the recent 
number of people with CKD >45 years old will be markedly increased, 
taking into consideration that the estimated glomerular filtration rate 
(eGFR) decreases by 0.75 - 1.00 mL/min and, for example, 50% of UK 
children born in 2007 will live to the age of 103 years.[5] Although no 
figures for CKD are available in South Africa (SA), it is highly likely 
that these will be higher in the majority of the SA public, given that 
end-stage renal failure (ESRF) (CKD stage 5) is 3 - 4 times more prev-
alent in Afro-Americans.[6] Mayosi et al.[7] have shown that chronic 
renal failure (CRF) was the fifth most common cause of death in 
SA in 2006. The graph depicted in their article refers to deaths from 
nephritis/nephrosis only; therefore, the figure would probably have 
been much higher on the list if other causes of ‘renal death’, i.e. ESRF, 
were included. Permutations on how to prevent, diagnose, effectively 
treat and slow progression to ESRF, published in the CME section of 
the March and April 2015 editions of the SAMJ, were supported by 
a guest editorial written by the Minister of Health, Dr A Motsoaledi.[8-10] 
This was followed by a ministerial summit held in Ekurhuleni in March 
2015 on how to handle the burden of CKD in our resource-limited 
country. An additional burden is that the 2014 Renal Registry report-
ed that 9.3% of all patients with ESRD on dialysis are HIV-positive. 
We believe that prevention, early detection and significantly slowing 
the progression of renal functional deterioration are of pivotal impor-
tance. The guidelines on how to achieve these skills are well illustrat-
ed in the SAMJ CME articles and in the Kidney Disease: Improving 
Global Outcomes (KDIGO) guidelines for CKD[11] (the latter are 
currently being reviewed, specifically for low- and middle-income 
countries). We urge all relevant health personnel in the public, private 
and government sectors to read these guidelines.
To clarify the classification of CKD, a simplified version is shown 
in Table 1. As ˂10% of the calculated potential sufferers of ESRF in 
the public sector of SA are able to receive renal replacement therapy 
(RRT), prevention strategies demand the utmost attention and are of 
essential importance in all healthcare protocols. 
Since the publication of the guideline of the National Kidney 
Foundation of South Africa (NKFSA), various new avenues for 
prevention/slowing progression have come to light. The six ‘caveats’, 
which form the basis of this article, are shown in Table 2 and are 
discussed in that order.
Diabetes and metformin
Metformin (MF) must be regarded as the gold standard of treatment 
in patients with type 2 diabetes mellitus (DM).[12] Its advantages are 
shown in Table 3. Of particular relevance is the continually increasing 
number of patients ˂50 years of age diagnosed with diabetes. In 
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CKD 1 90 - 110 Normal function
CKD 2 60 - 89 Asymptomatic
CKD 3a 45 - 59 Subclinical symptoms
CKD 3b 30 - 44 Mild clinical symptoms
CKD 4 15 - 29 Moderate to severe 
symptoms
CKD 5 <15 At or nearly at ESRF
CKD = chronic kidney disease; ESRF = end-stage renal failure.
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addition to the multiple cardiovascular and renal complications of DM, 
renal dysfunction in the elderly is further compounded by the slow but 
progressive fall in glomerular filtration rate (GFR) in persons >45 years 
of age (i.e. ±1 mL/min/year) and also because people live longer.
For many years the US Food and Drug Administration (FDA), 
the Regulatory Cooperation Council (RCC) in Canada and other 
regulatory bodies have indicated that the use of MF is contraindicated 
in patients with mild and moderate CKD (stages 3a and 3b) owing to 
the rarely reported but life-threatening complication of lactic acidosis 
(LA) (serum lactate levels ≥15 mmol/L).
That LA does not occur in patients who receive MF, with an esti-
mated GFR (eGFR) of 50 - 30 mL/min., has been indicated in studies 
conducted by Inzucchi et al.[13] They showed that MF can be safely 
used in these patients, provided that certain guidelines are always 
followed. A Coch rane meta-analysis conducted on 47 096 patients 
with a follow-up of 86 067 patient-years compared the incidence of 
LA in patients who received MF with those who did not, irrespective of the 
eGFR.[14] They found that for the upper limit of 95% confidence the 
true incidence of LA was 6.3/100 000 patient-years for the MF group 
and 7.8/100 000 patient-years for the non-MF group. 
It is important to remember that before prescribing MF for any 
degree of renal function, certain rules are essential and must be fully 
adhered to. As many practitioners are either unaware or uncertain of 
the predisposing conditions, these are set out in Table 4. 
Mechanisms of MF-associated LA are not well elucidated, but include 
conversion of glucose to lactate in the splanchnic bed and inhibition of 
hepatic gluconeogenesis (i.e. from lactate, pyruvate and adenine).[15,16] 
It is essential that any patient with the abovementioned precipi ta ting 
disorders is instructed to immediately but temporarily withdraw the 
use of MF and present to a doctor. Patients have to be instructed in 
writing of the abovementioned dangers. If the warnings are adhered 
to, it is uncertain whether even CKD stage 4 or 5 per se could cause 
LA. However, it still remains preferable to avoid MF in the above-
mentioned patient cohorts until further information is available. Of 
note, to date only 4 patients with ESRF on peritoneal dialysis, who 
were on MF, have developed LA. Three of the 4 had LA-precipitating 
factors, as mentioned in Table 4.[17] 
The dialysate in continuous ambulatory peritoneal dialysis (CAPD) 
contains lactate that may predispose to LA, even in the presence of 
normal hepatic function; it is a definite contraindication to the use 
of MF. A literature search on LA in haemodialysis (HD) yielded no 
data, probably because of non-usage of MF. However, HD utilises a 
bicarbonate buffer in the dialysate and, therefore, carefully conducted 
research into MF use may be of value.
The reason for emphasising the use of MF in CKD relates to both 
its immense value in glucose control in DM and to the necessity of 
slowing/preventing progression of both ESRF and cardiovascular 
disease (CVD) complications in a country with limited resources for 
the adequate funding of RRT. The last important consideration is that 
for many reasons patients with CKD stage 4 or 5 or those on dialysis 
commonly exhibit widely fluctuating glucose levels. Hypoglycaemia 
is extremely common, not only in patients receiving insulin but also 
because of drug accumulation in those on oral antidiabetic drugs. 
Dipeptidyl peptidase-4 inhibitors (i.e. incretins) together with 
basal long-acting insulin would be the safest in the case of HD.[18] 
The addition of MF would need to be carefully studied, if considered.
Also to be noted in the treatment of diabetes is the development of 
a novel, potentially life-saving, antidiabetic class of drug, the sodium-
glucose cotransporter-2 (SGLT-2) inhibitors.[19] These drugs block 
the proximal tubular reabsorption of glucose, leading to glycosuria. 
It also results in increased sodium loss. Other beneficial effects 
described were: (i) excellent diabetic control; (ii) no side-effects 
and very well tolerated; (iii) marked reduction in hypertension and 
vascular morbidity; and (iv) significant renoprotection. If used early 
on in the disease, it could theoretically prevent most of the comorbid 
vascular and renal effects of sub-optimally treated type 2 diabetes. 




It has been reported that autosomal-dominant polycystic kidney 
disease (ADPKD) occurs in ~1:1 000 people.[20] The AD in ADPKD 
has been changed from adult to autosomal-dominant because the 
disease can manifest not only in childhood, but even in utero.[21,22] In an 
excellent and recent review of genetics and pathogenetic mechanisms 
of cyst formation, clinical and diagnostic investigation parameters 
Table 2. Recent advances in slowing the progression of 
chronic kidney disease
Modality Method and mode of functional stabilisation
Type 2 diabetes Safety data on the use of MF in diabetes in 
CKD stages 
ADPKD Slowing CKD with statin therapy
Acidosis Early treatment of mild acidosis using 
bicarbonate (oral)
Gut metabolites TMAO in CKD reduced by red meat avoidance 
from CKD stage 3b onwards
Uric acid Allopurinol to slow down progression from 
CKD stage 3b onwards
Exercise From CKD stage 3 onwards
CKD = chronic kidney disease; MF = metformin; ADPKD = autosomal-dominant 
polycystic kidney disease; TMAO = trimethylamine N-oxide. 
Table 3. Advantages of metformin
• Excellent absorption and widespread distribution
• Increases intracellular glucose uptake, especially in muscular 
tissue
• Decreases insulin resistance
• Decreases hepatic glycogenolysis
• Decreases appetite
• Decreases the intensity of diabetic macro- and microvascular 
disease and thereby prevents/slows cardiovascular complications 
of diabetes
• Does not cause hypoglycaemia
• Improves quality of life
• Moderate lowering effect on low-density lipoprotein cholesterol 
and triglycerides
• Inexpensive
Table 4. Factors precipitating lactic acidosis in patients with 




• Any hypoxic state
• Clinical dehydration
• Shock (especially septic shock)
• Severe sepsis and haemodynamic instability 
• Major surgery
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and recent treatments, Mochizuki et al.[20] outlined several potential 
therapies for ADPKD. Tolvaptan and the vasopressin V2-receptor 
antagonists that inhibit cyst and kidney volume growth have been 
shown to be of value in the treatment of ADPKD. However, the effects 
are partial, there are many side-effects and the agents would probably 
be prohibitively expensive in SA. Likewise, somatostatin (octreotide) 
and the mammalian target of rapamycin (mTOR) inhibitor rapamycin 
have been used, but with limited or disappointing results, and are also 
excessively expensive.[20,23]
Cadnapaphornchai et al.[24] recently reported on the prevention 
of a reduction in kidney volume and cyst growth, which was 
accom panied by kidney functional stability, using pravastatin in 
children and adults, with striking results. The use of statins is 
not new and both experimental and clinical mechanisms of renal 
protection in ADPKD have previously been shown. The mechanisms 
underlying the effects of statins on renal structural protection are still 
speculative, but may be related to their ability to prevent synthesis 
of certain isoprenoids that prevent post-translational modification 
of proteins such as Ras and Rho. Their signal translation would be 
altered, affecting cell proliferation and polarity. The blockage of these 
isoprenoids would reduce formation and growth of kidney cysts. In 
addition, statins inhibit angiogenesis.[24] It would be interesting to 
investigate whether the production of glycogen synthase kinase-3β 
(GSK3β) is altered. GSK3β has recently been shown to play a role in 
ADPKD via induction of proliferation of cystic epithelial cells.
The following recommendations have been suggested. All children 
from the age of ~10 years and all adults from ADPKD families 
should be screened using magnetic resonance imaging (MRI) or 
computed tomography (CT), but not renal ultrasound (due to the 
considerable number of negative results). High-dose statins must be 
administered, e.g. atorvastatin 40 - 80 mg or rosuvastatin 20 - 40 mg 
is probably preferable to pravastatin. Even at these doses, generics are 
inexpensive, but the usual side-effects should be monitored. It should 
be noted that statins have not been approved for use in ADPKD. The 
risks and benefits should be discussed with patients and relatives, 
and should include either signed parental or patient consent. In 
a disease that is responsible for 5 - 8% of all cases of ESRF, statins 
present a major and affordable preventive treatment in patients with 
ADPKD and constitute a significant advance in the management of 
these patients. 
Acidosis
Recent studies have focused on the harm that small changes in the 
level of blood acidity can cause, even in patients with mild renal 
dysfunction (CKD stage 2). Łoniewski and Wesson[25] discuss various 
possible causes of renal damage caused by chronic acidosis, such as 
increased endothelin, aldosterone and angiotensin II production, 
inflammation and renal fibrosis. 
In support of the necessity to control acidosis, there are two 
further studies. Banerjee et al.[26] have clearly shown that diet-
induced acid load is associated with increased risk of ESRF. They 
demonstrated that worsening of metabolic acidosis was highly 
significantly associated with a decrease in GFR and concluded that 
acidosis in CKD is independently associated with an increased risk of 
ESRF.[26] Secondly, a recent study from the University of Manchester, 
UK, showed that small changes in blood acidity are associated with 
an increase in parathyroid secretion, resulting in removal of calcium 
and phosphate from bones with arterial metastatic deposition.[27] The 
optimal NaHCO3 dose remains to be determined, but the current 
recommendations state a dose of 0.5 - 1.0 mmol of NaHCO3/kg body 
weight in three divided doses per day, i.e. 1 or 2 small salt spoons of 
baking soda three times a day with meals.
Many pathogenetic mechanisms in the progression of renal dysfunc-
tion associated with metabolic acidosis have been demonstrated, 
which mandates active and ongoing prevention of acidosis in patients 
with moderate to mild CKD. Of note is the recommendation that 
only sodium bicarbonate should be used, as agents such as sodium 
citrate could pose a threat of increased dietary aluminium absorp-
tion in patients with more advanced CKD, but who are not yet on 
dialysis.[28,29] 
Gut bacterial by-products linked to 
CKD progression and CKD-associated 
cardiovascular disease 
Recent studies have suggested involvement of gut bacteria in the 
generation of metabolites that display uraemic toxicity. Further 
experiments by Tang et al.[30] investigated the effects of gut micro-
bial-dependent trimethylamine N-oxide (TMAO) in patients 
with CKD. Elevated TMAO plasma levels were demonstrated in 
patients with CKD and have been shown to contribute signifi-
cantly to progressive renal fibrosis, CVD and poorer long-term 
survival. Studies in animals that were fed an increased content of 
TMAO in their diet confirmed a marked increase in renal fibrosis 
and dysfunction. Furthermore, in a cohort of people with normal 
renal function but on a high meat diet, the risk of microalbuminuria 
has been clearly demon strated.[31,32] TMAO metabolites comprise 
choline, phosphatidylcholine (lecithin) and L-carnitine, and the 
levels are particularly high in red meat, liver, other meats and egg 
yolk. Lower levels are found in poultry. It is important to remem-
ber that choline is an essential nutrient that can be obtained from 
red meat, as well as from fish, poultry and eggs. Therefore, in 
recommending avoidance of or a stringent reduction in the inges-
tion of red meat and pork, one could reasonably anticipate that 
this will significantly slow renal functional decline even before 
the results of interventional studies are available. Two further 
strong theoretical points support the supposition that avoidance 
of red meat significantly reduces the hydrogen ion dietary load 
(discussed above). Red meats contain significantly more phos-
phate than poultry and fish. It is known that, because a decrease 
in renal phosphate clearance occurs early on in CKD, even a mild 
tendency to increase the body’s phosphate levels increases the 
production of fibroblast growth factor 23 (FGF23) and depresses 
the Klotho FGF23-receptor pathway.[33,34] This effect will result 
in a decrease in the activity of the renal tubular 1α-reductase 
enzyme, resulting in a significant reduction in the conver sion of 
inactive vitamin D3 into active vitamin D3 (calcitriol). Therefore, 
less calcium will be absorbed in the gut, eventually resulting in 
hypocalcaemia and secondary hypoparathyroidism, which is a 
well-known factor in the genesis of progressive renal functional 
deterioration. 
Because of severe financial constraints in the treatment of 
advanced CKD in SA, it seems prudent to suggest this dietary 
advice in anyone with an eGFR of ≤50 mL/min. 
Serum uric acid
Observational studies suggest that uric acid (UA) is an indepen dent 
predictor of both progression of CKD and increased mortality from 
CVD. It has also been proposed that an elevated UA may have a role 
in initiating hypertension, nephrosclerosis and insulin resistance.[35-38] 
These are not new findings, but it is currently uncertain whether 
a raised UA acts as a nephrotoxin, vasculo toxin, or marker of a 
high acid-ash (protein) diet or reduced eGFR. Although trials have 
demonstrated slowing of CKD progression in patients treated with 
allopurinol, the numbers are limited. Both the KDIGO, USA, and 
733       September 2017, Vol. 107, No. 9
CME
the National Institute for Clinical Excellence (NICE), UK, do not 
recommend UA-lowering therapy. However, there is a plethora of 
experimental studies that support the notion that UA reduction may 
not only be renoprotective but may be important in reducing CVD 
mortality.[39] As CVD is a major risk factor in CKD, and as RRT is so 
limited, it would not seem unreasonable to recommend careful use 
of allopurinol in patients with asymptomatic hyperuricaemia from 
CKD stage 3 onwards, commencing when the UA level rises above 
the normal range. All dietary measures should be tried before admin-
istering allopurinol. In a key article, Kang and Nakagawa[38] stated 
that experimental data using hyperuricaemic animals and cultured 
cells provide robust evidence regarding hypertension, proteinuria, 
vascular disease and progressive renal scaring. Nevertheless, in 1984 
Hande et al.[40] reported on severe allopurinol toxicity with fever, 
rash, eosinophilia and worsening of renal function in 78 patients with 
varying degrees of CKD. However, all 78 patients received concomi-
tant thiazide diuretics for hypertension. Since that publication, rare 
cases of this syndrome have been reported in patients with CKD and 
normal renal function. It is considered as an idiosyncratic reaction 
that occurs very rarely.
Our advice is to start allopurinol in small doses (e.g. 100 mg/day), 
monitor the patient and titrate up to produce an adequate UA-lowering 
effect if no toxicity is found. Furthermore, we would recommend 
that if a CKD patient is receiving a thiazide, allopurinol should be 
avoided. 
Exercise
There are many studies investigating the effects of exercise in patients 
with CKD who are not on dialysis. The results are encouraging and 
have demonstrated multiple benefits in both slowing progression and 
reducing mortality (Table 5).[41]
All exercise training programmes should be evaluated and 
supervised by trained medical personnel and the patient’s clinical 
status carefully evaluated before prescribing exercise.
Conclusion
As financial constraints in SA permit that only a fraction of public 
sector ESRF patients are able to receive RRT, it would be logical to use 
all safe mechanisms to slow progressive loss of GFR. Therefore, apart 
from the usual advice of smoking cessation, alcohol moderation, 
maintaining ideal body weight, avoiding nephrotoxins, maintaining 
blood pressure and blood sugar at target levels, and reducing protein-
uria using well-known prescribed methods, we advise the use of all 
other possible but safe modalities to slow functional deterioration. 
The safe use of MF in CKD (excluding CKD stage 5), early screen-
ing and safe inexpensive treatment of patients with ADPKD, use of 
allopurinol in the absence of gout to decrease UA levels, treatment 
of acidosis and dietary and prescribed exercise programmes should 
be included in the list of progression-slowing procedures. Of note is 
that even this extended list indicates that changes in lifestyle as well 
as therapeutic measures should be employed. 
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Table 5. Exercise and chronic kidney disease
Type of exercise Benefit
Resistance training Decrease in CRP and IL-6
Swimming Decrease in oxidative stress and 
BP, and increase in eGFR
General exercise Improved VO2 max, BP and eGFR 
CRP = C-reactive protein; IL-6 = interleukin 6; VO2 max = maximum volume of oxygen; 
BP = blood pressure; eGFR = estimated glomerular filtration rate.
